ombrabulin ombrabulin ombrabulin was an experimental drug candidate discovered by ajinomoto and further developed by sanofi-aventis. ombrabulin is a combretastatin a-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth. ombrabulin names iupac name n1--l-serinamide systematic iupac name (2s)-2-amino-3-hydroxy-n-propanamide other names ave-8062; ave-8062a; ac7700; cs-39-l-ser.hcl identifiers cas number 181816-48-8 y253426-24-3 (hcl) y 3d model (jsmol) interactive image chemspider 5293602 n pubchem cid 69184056918404 (hcl) unii 82jb1524q6 ykxz9ndo6h0 (hcl) y comptox dashboard (epa) dtxsid50939477 inchi inchi=1s/c21h26n2o6/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3/h5-11,15,24h,12,22h2,1-4h3,(h,23,25)/b6-5-/t15-/m0/s1 nkey: ixwntlstozfscm-yvacavlksa-n ninchi=1/c21h26n2o6/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3/h5-11,15,24h,12,22h2,1-4h3,(h,23,25)/b6-5-/t15-/m0/s1key: ixwntlstozfscm-yvacavlkbs smiles coc1=c(c=c(c=c1)/c=c\c2=cc(=c(c(=c2)oc)oc)oc)nc(=o)(co)n properties chemical formula c21h26n2o6 molar mass 402.447 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references it was granted orphan drug status by the european medicines agency in april 2011. in january 2013, sanofi said it discontinued development of ombrabulin after disappointing results from phase iii clinical trials.